Qiagen slightly misses earnings expectations, causing mixed reactions from analysts.

Qiagen, a life sciences company, updated its FY 2025 earnings guidance to $2.28 EPS, slightly below analyst expectations of $2.35. The company's Q1 2025 guidance is $0.50 EPS. Analysts have mixed views, with HSBC downgrading to "hold" and Jefferies reaffirming a "buy" rating. Qiagen's stock saw a midday trading boost to $43.76, with a consensus target of $50.07. The company offers solutions for processing biological samples and has a market cap of $9.71 billion.

5 weeks ago
10 Articles